You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

16 Results
Drug
Other Name(s): Tarceva®
Quick Link(s): Drug Monograph, Patient Info Sheet
Oct 2022
Drug
Quick Link(s): Drug Monograph, Patient Info Sheet
Nov 2022
Drug
Other Name(s): Rydapt®
Quick Link(s): Drug Monograph, Patient Info Sheet
Jun 2022
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Adjuvant, Palliative
Drugs Used:
methotrexate,
vinBLAStine,
DOXOrubicin,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
methotrexate
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2022
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    erlotinib - Incurable progressive NSCLC, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
erlotinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2022
Regimen
Cancer Type:
Genitourinary, 
Prostate
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), with specific clinical criteria
Exceptional Access Program
    enzalutamide - For the treatment metastatic castration sensitive prostate cancer (mCSPC), with specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
enzalutamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2022
Regimen
Cancer Type:
Head and Neck
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
erlotinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2022
Regimen
Cancer Type:
Gynecologic, 
Vulva
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
erlotinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2022
Regimen
Cancer Type:
Hematologic, 
Rare Diseases
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
midostaurin (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
riTUXimab (Unfunded),
methotrexate,
vinCRIStine,
procarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2022
Guidelines and Advice
Status: Current
ID: PET 2021-1
Jan 2022

Pages